Mesothelioma Stratified Therapy (MiST): A stratified multi-arm phase IIa clinical trial to enable accelerated evaluation of targeted therapies for relapsed malignant mesothelioma. - Mesothelioma Stratified Therapy (MiST)

niversity of Leicester0 个研究点目标入组 120 人开始时间: 2018年7月3日最近更新: 2019年12月16日

适应症

试验速览

暂无简介。

•Stage 1: Registration Inclusion Criteria:
•Histologically confirmed MM an available biopsy for research
•Male or female patients aged = 18 years.
•Expected survival of =12 weeks or greater
•ECOG PS 0-1
•CT scan chest, abdomen (and pelvis if applicable) confirming disease progression Patients must have received at least one prior line of therapy to include a platinum doublet first-line chemotherapy (within or outside of another clinical trial)
•Willing to consent for molecular screening of archived tumour block (PIS1 &
•Stage 2: Treatment
•Based on the result of Stage 1 (registration), patients will be enrolled according to the MiST arm eligibility criteria which will be protocol specific.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 0
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 0

•Stage 1: Registration Exclusion Criteria:
•Patients with a diagnosis of a second malignancy except prostate or cervical cancer in remission, patients with a diagnosis of basal cell carcinoma of the skin or superficial bladder cancer.
•Uncontrolled CNS disease. Asymptomatic brain metastases are allowed if previously treated with radiotherapy > 28 days prior to starting the investigational agent.
•New York Heart Association Class II or greater congestive heart failure.
•Patients with severe hepatic insufficiency or severe renal impairment.
•Patients requiring long term oxygen therapy.
•Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.
•Stage 2: Treatment
•Please refer to the exclusion criteria of the specific treatment protocol.

发起方

niversity of Leicester